Living Cell Technologies Limited (LCT) - Articles and news items

NTCELL Phase I/IIa study meets endpoints

Industry news / 15 June 2015 / Victoria White

A Phase I/IIa study of NTCELL, an regenerative cell therapy being studied as a disease-modifying agent in Parkinson’s disease, has met its endpoints…

 

The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...
+